Ken K Tsang, Vivian W K Hui, Christopher M K Pang, Ziqi Tang, Dawei Yang, Truong X Nguyen, Shaheeda Mohamed, Timothy Y Y Lai, Carol Y Cheung, Simon K H Szeto
{"title":"基于sd - oct的生物标志物预测抗vegf治疗视网膜静脉闭塞继发黄斑水肿的治疗结果。","authors":"Ken K Tsang, Vivian W K Hui, Christopher M K Pang, Ziqi Tang, Dawei Yang, Truong X Nguyen, Shaheeda Mohamed, Timothy Y Y Lai, Carol Y Cheung, Simon K H Szeto","doi":"10.1111/aos.17574","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the role of spectral domain optical coherence tomography (SD-OCT)-based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti-vascular endothelial growth factor (VEGF) therapy.</p><p><strong>Methods: </strong>Retrospective cohort study including consecutive cases of RVO associated MO who received anti-VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD-OCT-based biomarkers, including vitreomacular status, size of intra-retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper-reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF).</p><p><strong>Results: </strong>One hundred and thirty eyes were included with 81 and 49 eyes in the BRVO and CRVO subgroup, respectively. In both subgroups, baseline disrupted EZ/ELM [BRVO: (β = 0.144 p = 0.008; β = 0.111 p = 0.014; β = 0.096 p = 0.042) and CRVO: (β = 0.316 p < 0.001; β = 0.336 p < 0.001; β = 0.327 p < 0.001)] were associated with worse VA from baseline through 24 months. In the BRVO subgroup, the presence of HRF (β = 0.209 p < 0.001) correlated with worse baseline VA. Improvement in DRIL extent [OR = 4.355 (1.109-17.094) p = 0.035; OR = 4.510 (1.707-11.917) p = 0.002] and EZ/ELM integrity [OR = 4.474 (1.783-11.223) p = 0.001; OR = 3.214 (1.414-7.305) p = 0.005] were associated with a higher likelihood of achieving at least a 5 letters gain at 12 and 24 months.</p><p><strong>Conclusion: </strong>A comprehensive system of SD-OCT-based features could predict functional outcomes of MO secondary to RVO with anti-VEGF therapy up to 24 months.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SD-OCT-based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti-VEGF therapy.\",\"authors\":\"Ken K Tsang, Vivian W K Hui, Christopher M K Pang, Ziqi Tang, Dawei Yang, Truong X Nguyen, Shaheeda Mohamed, Timothy Y Y Lai, Carol Y Cheung, Simon K H Szeto\",\"doi\":\"10.1111/aos.17574\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the role of spectral domain optical coherence tomography (SD-OCT)-based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti-vascular endothelial growth factor (VEGF) therapy.</p><p><strong>Methods: </strong>Retrospective cohort study including consecutive cases of RVO associated MO who received anti-VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD-OCT-based biomarkers, including vitreomacular status, size of intra-retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper-reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF).</p><p><strong>Results: </strong>One hundred and thirty eyes were included with 81 and 49 eyes in the BRVO and CRVO subgroup, respectively. In both subgroups, baseline disrupted EZ/ELM [BRVO: (β = 0.144 p = 0.008; β = 0.111 p = 0.014; β = 0.096 p = 0.042) and CRVO: (β = 0.316 p < 0.001; β = 0.336 p < 0.001; β = 0.327 p < 0.001)] were associated with worse VA from baseline through 24 months. In the BRVO subgroup, the presence of HRF (β = 0.209 p < 0.001) correlated with worse baseline VA. Improvement in DRIL extent [OR = 4.355 (1.109-17.094) p = 0.035; OR = 4.510 (1.707-11.917) p = 0.002] and EZ/ELM integrity [OR = 4.474 (1.783-11.223) p = 0.001; OR = 3.214 (1.414-7.305) p = 0.005] were associated with a higher likelihood of achieving at least a 5 letters gain at 12 and 24 months.</p><p><strong>Conclusion: </strong>A comprehensive system of SD-OCT-based features could predict functional outcomes of MO secondary to RVO with anti-VEGF therapy up to 24 months.</p>\",\"PeriodicalId\":6915,\"journal\":{\"name\":\"Acta Ophthalmologica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Ophthalmologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/aos.17574\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aos.17574","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨基于光谱域光学相干断层扫描(SD-OCT)的生物标志物在预测视网膜静脉闭塞(RVO)继发黄斑水肿(MO)对抗血管内皮生长因子(VEGF)治疗反应中的作用。方法:回顾性队列研究,包括在2020年1月至2021年4月期间连续接受抗vegf注射的RVO相关MO病例。基线、12和24个月的LogMAR视力(VA)与一系列基于sd - oct的生物标志物相关,包括玻璃体黄斑状态、视网膜内囊肿(IRC)的大小、视网膜内层紊乱(DRIL)的存在、视网膜超反射灶(HRF)、外限制膜(ELM)的完整性、椭球区(EZ)、锥形外段尖端(COST)和视网膜下液(SRF)的存在。结果:共纳入130只眼,BRVO亚组81只眼,CRVO亚组49只眼。在两个亚组中,基线EZ/ELM紊乱[BRVO: (β = 0.144 p = 0.008;β = 0.111 p = 0.014;结论:基于sd - oct特征的综合系统可以预测抗vegf治疗24个月后RVO继发MO的功能结局。
SD-OCT-based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti-VEGF therapy.
Purpose: To investigate the role of spectral domain optical coherence tomography (SD-OCT)-based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti-vascular endothelial growth factor (VEGF) therapy.
Methods: Retrospective cohort study including consecutive cases of RVO associated MO who received anti-VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD-OCT-based biomarkers, including vitreomacular status, size of intra-retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper-reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF).
Results: One hundred and thirty eyes were included with 81 and 49 eyes in the BRVO and CRVO subgroup, respectively. In both subgroups, baseline disrupted EZ/ELM [BRVO: (β = 0.144 p = 0.008; β = 0.111 p = 0.014; β = 0.096 p = 0.042) and CRVO: (β = 0.316 p < 0.001; β = 0.336 p < 0.001; β = 0.327 p < 0.001)] were associated with worse VA from baseline through 24 months. In the BRVO subgroup, the presence of HRF (β = 0.209 p < 0.001) correlated with worse baseline VA. Improvement in DRIL extent [OR = 4.355 (1.109-17.094) p = 0.035; OR = 4.510 (1.707-11.917) p = 0.002] and EZ/ELM integrity [OR = 4.474 (1.783-11.223) p = 0.001; OR = 3.214 (1.414-7.305) p = 0.005] were associated with a higher likelihood of achieving at least a 5 letters gain at 12 and 24 months.
Conclusion: A comprehensive system of SD-OCT-based features could predict functional outcomes of MO secondary to RVO with anti-VEGF therapy up to 24 months.
期刊介绍:
Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER).
Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.